CASP4 and neoplasm: A previous study has identified tumor-associated CASP4 as a new diagnosis, prediction and prognosis biomarker for NSCLC patients (Terlizzi et al., 2018), nevertheless, the relation of the CASP4-mediated pyroptosis with LUSC development is still unknown.